Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.46 |
| ▸ | CCR2 | P41597 | 4/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.30 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.30 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.30 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.30 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.30 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22034304 | 0.84 | TRPV4 (0.40) | TRPV4CCR2ALDH1A1HSD17B10TDP1 | |
| SCHEMBL15465525 | 0.84 | TRPV4 (0.40) | TRPV4CCR2TNFRIPK1ALDH1A1 | |
| SCHEMBL31567040 | 0.81 | TRPV4 (0.42) | TRPV4CCR2ALDH1A1HSD17B10 | |
| SCHEMBL14812406 | 0.80 | CCR4 (0.40) | TRPV4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL20485996 | 0.80 | CA2 (0.45) | — | |
| SCHEMBL15575771 | 0.77 | FABP4 (0.35) | TRPV4CCR2ALDH1A1 | |
| SCHEMBL31566482 | 0.77 | TRPV4 (0.39) | TRPV4CCR2ALDH1A1 | |
| SCHEMBL31566968 | 0.77 | TRPV4 (0.50) | TRPV4CCR2ALDH1A1 | |
| SCHEMBL788147 | 0.76 | TRPV4 (0.44) | TRPV4ALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL31556483 | 0.76 | TRPV4 (0.44) | TRPV4ALDH1A1HSD17B10TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467976-B1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| WO-2011081310-A3 | PEPTIDE MARKER FOR CANCER DIAGNOSIS, AND CANCER DIAGNOSIS METHOD USING SAME | 한국기초과학지원연구원 (KR) | 2011-10-27 | — | — | WO | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | BAXTER ANDREW | 2010-04-01 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | TRPV4 1264/4885CCR2 3/4885TNF 944/4885 |
| US-20100081670-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | CCL11, CCL2, CCR2 | TRPV4 1264/4885CCR2 3/4885TNF 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.